AnaptysBio (NASDAQ:ANAB) Posts Earnings Results, Beats Expectations By $0.58 EPS

AnaptysBio (NASDAQ:ANAB) issued its quarterly earnings data on Tuesday. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.72) by $0.58, Zacks reports. AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%. The business had revenue of $30.02 million during the quarter, compared to the consensus estimate of $7.92 million.

AnaptysBio Stock Up 11.7 %

Shares of AnaptysBio stock opened at $22.21 on Thursday. AnaptysBio has a 12-month low of $13.36 and a 12-month high of $41.31. The firm has a market capitalization of $609.31 million, a PE ratio of -3.50 and a beta of -0.24. The stock’s fifty day moving average is $33.30 and its 200-day moving average is $29.89.

Insider Activity at AnaptysBio

In other AnaptysBio news, insider Paul F. Lizzul sold 1,500 shares of the company’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $38.67, for a total transaction of $58,005.00. Following the completion of the sale, the insider now directly owns 15,398 shares of the company’s stock, valued at approximately $595,440.66. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Paul F. Lizzul sold 1,500 shares of the firm’s stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total value of $58,005.00. Following the completion of the sale, the insider now owns 15,398 shares of the company’s stock, valued at $595,440.66. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder Ecor1 Capital, Llc purchased 273,972 shares of the stock in a transaction dated Wednesday, August 14th. The shares were acquired at an average price of $36.50 per share, for a total transaction of $9,999,978.00. Following the acquisition, the insider now directly owns 7,794,996 shares of the company’s stock, valued at $284,517,354. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Insiders sold 22,440 shares of company stock worth $892,936 in the last quarter. 33.70% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of brokerages have issued reports on ANAB. HC Wainwright reduced their price target on AnaptysBio from $55.00 to $52.00 and set a “buy” rating for the company in a research report on Wednesday. Truist Financial upped their price objective on shares of AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a report on Thursday, August 15th. Guggenheim raised their target price on shares of AnaptysBio from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Monday, October 21st. UBS Group upped their price target on shares of AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. Finally, Wedbush reiterated an “outperform” rating and set a $42.00 price objective on shares of AnaptysBio in a research note on Wednesday. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $55.45.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.